Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380 | 1.00 | HTT (1.00) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8392088 | 1.00 | HTT (1.00) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8396675 | 1.00 | HTT (1.00) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8395096 | 1.00 | HTT (1.00) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL25708013 | 1.00 | HTT (1.00) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27819236 | 0.98 | HTT (0.96) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8391614 | 0.98 | HTT (0.96) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL4397011 | 0.96 | HTT (0.92) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8393766 | 0.96 | HTT (0.92) | HTTPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL8393313 | 0.93 | HTT (0.88) | HTTPOLBHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367867-B1 | COMPOUNDS WITH GUANIDINE STRUCTURE AND USES THEREOF AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS | BLUESTAR SILICONES FRANCE (FR) | 2018-01-03 | — | — | EP | disclosed |
| CN-104395292-B | 1 substituted indazole derivative | 大日本住友制药株式会社 | 2017-03-01 | — | — | CN | disclosed |
| US-8871889-B2 | Compounds with guanidine structure and uses thereof as organopolysiloxane polycondensation catalysts | BLUESTAR SILICONES FRANCE SAS (FR) | 2014-10-28 | — | — | US | disclosed |
| CN-102575011-B | Silicone composition crosslinkable by dehydrocondensation in the presence of a non-metallic catalyst | BLUESTAR SILICONES FRANCE | 2014-03-12 | — | — | CN | disclosed |
| US-20130253134-A1 | COMPOUNDS WITH GUANIDINE STRUCTURE AND USES THEREOF AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS | BLUESTAR SILICONES FRANCE (FR) | 2013-09-26 | — | — | US | disclosed |
| EP-2443208-B1 | METHOD FOR COATING A TIN-FREE SILICON COMPOSITION ON A FLEXIBLE MEDIUM | BLUESTAR SILICONES FRANCE (FR) | 2013-09-04 | — | — | EP | disclosed |
| US-8519079-B2 | Compounds with guanidine structure and uses thereof as organopolysiloxane polycondensation catalysts | BLUESTAR SILICONES FRANCE SAS (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8513370-B2 | Method for sealing and assembling components of a drive train | BLUESTAR SILICONES FRANCE SAS (FR) | 2013-08-20 | — | — | US | disclosed |
| CN-102459491-B | Method for sealing and assembling components of a drive train | BLUESTAR SILICONES FRANCE | 2013-08-07 | — | — | CN | disclosed |
| EP-2440628-B1 | METHOD FOR SEALING AND ASSEMBLING COMPONENTS OF A DRIVE TRAIN | BLUESTAR SILICONES FRANCE (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-1673087-A4 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7507753-B2 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005032484-A9 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1466904-A1 | BIARYL COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-4240954-A | CYCLOHEXYL UREAS OR THIOUREAS | AMERICAN CYANAMID COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | MC4R, MC3R, MC1R | HTT 636/4885POLB 4074/4885HSD17B10 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.